Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study

Pier Luigi Zinzani, Cinzia Pellegrini, Emanuela Merla, Filippo Ballerini, Alberto Fabbri, Attilio Guarini, Vincenzo Pavone, Gerlando Quintini, Benedetta Puccini, Maria Luigia Vigliotti, Vittorio Stefoni, Enrico Derenzini, Alessandro Broccoli, Letizia Gandolfi, Federica Quirini, Beatrice Casadei, Lisa Argnani, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

Current treatments for non-Hodgkin lymphomas are not optimally effective. Among new agents, bortezomib seems to play a pivotal role in the regulation of several cell pathways involved in the development of lymphomas. After results were obtained with clinical trials, we aimed to observe treatment with bortezomib in everyday clinical practice. We performed a multicenter retrospective analysis to assess the efficacy of bortezomib in heavily pretreated (median number of previous therapies 4, range 2-6) lymphoma patients in an off-label setting. Bortezomib therapy was scheduled for 4-6 cycles (1.3mg/m2 biweekly). Data from 50 patients were collected: 22% had a complete remission, 26% obtained a partial response and the remaining 52% was non-responder. According to histotype, we observed an overall response rate (ORR) of 51.6% in mantle cell lymphomas, an ORR of 60% among follicular lymphoma patients, and an ORR of 50% in the indolent nonfollicular lymphomas. None of diffuse large B-cell lymphoma patients obtained a response. Extra-hematological toxicity was really mild, and peripheral neuropathy occurred in only 5 patients; hematological toxicity was grades 3-4 thrombocytopenia in nine patients and grades 3-4 neutropenia in only three patients. In conclusion, treatment with bortezomib as single agent resulted safe and effective in a subset of heavily pretreated lymphoma patients with usually poor outcome. New future hypotheses of investigation are indicated.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalHematological Oncology
Volume31
Issue number4
DOIs
Publication statusPublished - Dec 2013

Keywords

  • Bortezomib
  • Observational
  • Relapsed lymphoma
  • Retrospective

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study'. Together they form a unique fingerprint.

  • Cite this

    Zinzani, P. L., Pellegrini, C., Merla, E., Ballerini, F., Fabbri, A., Guarini, A., Pavone, V., Quintini, G., Puccini, B., Vigliotti, M. L., Stefoni, V., Derenzini, E., Broccoli, A., Gandolfi, L., Quirini, F., Casadei, B., Argnani, L., & Baccarani, M. (2013). Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study. Hematological Oncology, 31(4), 179-182. https://doi.org/10.1002/hon.2036